Combining vaping with estrogen-containing medication raises the same core concern that has long been flagged for traditional cigarettes and birth control: blood clots. The direct evidence on e-cigarettes specifically is thin, with a 2015 systematic review finding zero published studies on cardiovascular risk in women using both hormonal contraception and e-cigarettes. But the biological mechanisms that make smoking dangerous alongside estrogen, including platelet activation, oxidative stress, and damage to blood vessel walls, have also been documented in vapers. Until large-scale studies catch up, the science that does exist suggests caution.
Why Estrogen and Vaping Worry Doctors
Estrogen-containing medications, whether birth control pills, hormone replacement therapy, or gender-affirming hormone therapy, nudge the body’s clotting system toward forming clots more readily. That shift is usually manageable on its own. Smoking, however, independently damages the inner lining of blood vessels and makes platelets stickier. When both forces act at the same time, the risk of dangerous clots, including deep vein thrombosis, pulmonary embolism, and stroke, rises sharply. This is why prescribers have warned against smoking while on combination birth control for decades.
E-cigarettes deliver many of the same vascular insults. A published case report describes a young woman who used both electronic cigarettes and oral contraceptives and developed bilateral pulmonary emboli along with a subacute stroke. The authors noted that because both traditional cigarettes and e-cigarettes increase platelet aggregation, oxidative stress, and vascular endothelial damage, “it is possible to see similar outcomes in women combining OCP use with electronic cigarettes.”1PubMed Central. Thromboembolism Triggered by a Combination of Electronic Cigarettes and Oral Contraceptives: A Case Report and Review of Literature A single case report does not prove causation, but the biological logic connecting the dots is well-supported.
The Evidence Gap
One of the most frustrating parts of this topic is how little direct research exists. When researchers conducted a systematic review specifically searching for evidence on cardiovascular risk among women using hormonal contraception and e-cigarettes, they found nothing. Not one study had been published on the subject at the time of their review.2Contraception. Hormonal contraception among electronic cigarette users and cardiovascular risk: a systematic review That gap has barely narrowed since. The consequence is that clinical advice about vaping and estrogen is largely extrapolated from decades of data on smoking and estrogen, bridged by newer lab and vascular studies on what e-cigarettes do to blood vessels. The reasoning is sound, but the specific risk estimates you might want, like “how much does vaping raise your clot risk compared to not vaping while on the pill,” simply do not exist yet.
How Vaping Damages Blood Vessels
The reason researchers draw parallels between smoking and vaping when it comes to clot risk is that both harm the endothelium, the single-cell layer lining every blood vessel. When the endothelium is healthy, it actively prevents clots from forming where they shouldn’t. When it is damaged or inflamed, the brakes come off.
A study exposing healthy, nonsmoking young adults to a single session of e-cigarette aerosol found that markers of oxidative stress and inflammation rose significantly within one to two hours, returning to baseline by about six hours. Crucially, this happened with nicotine-free e-liquid: the heating process, flavorings, and carrier solvents were enough on their own to trigger a measurable vascular stress response.3PubMed Central. Acute exposure to e-cigarettes causes inflammation and pulmonary endothelial oxidative stress in nonsmoking, healthy young subjects Other research has confirmed that e-cigarette exposure causes progressive endothelial dysfunction through specific oxidative pathways, and while nicotine makes the damage worse, it still occurs even without nicotine in the liquid.4PubMed Central. Electronic cigarette exposure causes vascular endothelial dysfunction due to NADPH oxidase activation and eNOS uncoupling
An older study from the traditional smoking era helps illustrate why endothelial damage specifically matters for people taking estrogen. In women who smoked and used oral contraceptives, smoking further reduced their production of prostacyclin, a compound that prevents platelets from clumping, and increased platelet aggregation. These effects were not seen in smokers who were not on oral contraceptives.5American Journal of Obstetrics and Gynecology. Evidence that smoking alters prostacyclin formation and platelet aggregation in women who use oral contraceptives The interaction between vascular damage and estrogen-driven clotting changes appears to be more than additive. The two together create conditions that neither would create alone.
Not All Estrogen Is Equal
If you are taking estrogen in some form, it matters a great deal which form. The clot risk tied to estrogen is not uniform across all products, and understanding why can change your practical risk profile considerably.
The biggest distinction is between oral estrogen (pills swallowed and processed by the liver) and transdermal estrogen (patches, gels, or sprays absorbed through the skin). In a randomized controlled trial comparing these routes in postmenopausal women, oral estradiol significantly increased markers of clotting activation and decreased antithrombin activity. Transdermal estradiol, by contrast, had no significant effect on these clotting markers.6PubMed. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial The reason is straightforward: when estrogen passes through the gut and liver before reaching the bloodstream, it stimulates the liver to produce extra clotting factors. When it enters through the skin, it largely bypasses that first-pass liver effect.
The type of estrogen molecule also matters. Most combined birth control pills use ethinyl estradiol, a synthetic estrogen that is far more potent in its effects on liver-produced clotting proteins than natural estradiol. A meta-analysis covering over half a million women found that users of pills containing natural estradiol (E2) had about a third lower risk of venous blood clots compared to users of ethinyl-estradiol-based pills.7Frontiers in Endocrinology. Are natural estrogens used in contraception at lower risk of venous thromboembolism than synthetic ones? A systematic literature review and meta-analysis A separate review confirmed that ethinyl estradiol’s potency in driving estrogen-sensitive liver proteins, including those involved in clotting, exceeds that of both estradiol and estetrol.8Contraception. Comparison of estrogenic components used for hormonal contraception
For someone who vapes and cannot or does not want to stop, these distinctions are relevant. A transdermal estrogen formulation sidesteps the liver-driven clotting surge. A pill using estradiol instead of ethinyl estradiol carries less clotting risk than the conventional pill. Neither removes the vascular harm from vaping itself, but reducing the clotting contribution from the estrogen side of the equation narrows the window of combined risk.
Nicotine-Free Vaping Is Not Risk-Free
Some people assume that if nicotine is the problem, switching to nicotine-free e-liquid solves the issue. The vascular research does not support that assumption. As mentioned earlier, endothelial dysfunction and oxidative stress occur even with nicotine-free vaping. The heated carrier liquids, propylene glycol and vegetable glycerin, produce reactive carbonyl compounds when aerosolized. Flavorings add their own chemical exposures. Nicotine makes things worse, but the baseline harm from inhaling heated aerosol is not zero.
A study in young female e-cigarette users measured microvascular endothelial function and found it was significantly reduced compared to non-users. The researchers had hypothesized that lower estradiol levels might explain why the endothelial damage was worse in women, but they found the opposite: estradiol levels were actually higher in the female e-cigarette users, suggesting that the vascular damage was being driven by other mechanisms entirely. Whatever was harming these women’s blood vessels, it was not a lack of estrogen, and having more estrogen did not protect them.
The practical implication is that swapping to zero-nicotine pods while staying on estrogen does reduce one risk factor (nicotine’s direct platelet and vascular effects) but does not eliminate the vascular damage from inhaling heated aerosol. It is a step in the right direction, not a complete solution.
Arterial Versus Venous Clots
Blood clots come in two broad flavors, and the risk factors for each differ in ways that matter here. Venous thromboembolism, which includes deep vein thrombosis and pulmonary embolism, is strongly linked to inherited clotting disorders. Arterial thrombosis, including stroke, is more closely tied to acquired risk factors like smoking.
An analysis of 770 women who had clotting events while on oral contraceptives found that inherited thrombophilia showed up in 42% of those with venous clots but only 24% of those with stroke. Cigarette smoking, on the other hand, was present in half of the stroke group versus a quarter of the venous clot group, a rate no higher than the general population for the venous group.9PubMed Central. Analysis of Risk Factors of Stroke and Venous Thromboembolism in Females With Oral Contraceptives Use In other words, smoking while on the pill disproportionately raises the risk of stroke specifically, not just clots in general.
This has two implications for vapers. First, if vaping mimics smoking’s vascular damage, the arterial side of the risk equation, including stroke, deserves particular attention. The case report mentioned earlier documented both pulmonary emboli and a stroke in the same patient, consistent with this pattern. Second, people with known inherited clotting conditions face elevated venous clot risk from estrogen alone, independent of vaping. For them, the combination may be especially dangerous because both pathways, arterial and venous, are compromised at once.
How Estrogen Affects Nicotine Cravings
There is an underappreciated wrinkle in this topic that makes quitting vaping harder for people on estrogen: estrogen itself appears to amplify nicotine’s rewarding effects. Women report stronger cigarette cravings during phases of the menstrual cycle when estradiol is higher. Animal studies have confirmed the pattern. In rats whose ovaries were removed, nicotine consumption dropped. When estradiol was supplemented back, nicotine intake partially rebounded, and estradiol specifically restored cue-triggered nicotine-seeking behavior that ovariectomy had abolished.10Neuropharmacology. Natural and synthetic estrogens specifically alter nicotine demand and cue-induced nicotine seeking in female rats Progesterone, by contrast, appears to have a protective effect against nicotine addiction.11PubMed Central. Role of progesterone in nicotine addiction: evidence from initiation to relapse
Further work has shown that estrogen acts on specific brain regions involved in reward and motivation. Estrogen receptors are found on neurons in the nucleus accumbens, a key area for addiction-related behavior. Estradiol treatment after ovariectomy altered the expression of estrogen receptor mRNA in this region and modified the neural plasticity associated with nicotine use.12eNeuro. Ovarian Hormones Regulate Nicotine Consumption and Accumbens Glutamatergic Plasticity in Female Rats This research is still in animal models, and the effects are complex. But the direction is consistent: exogenous estrogen may make nicotine harder to quit, which creates a frustrating feedback loop for someone told to stop vaping because they are on estrogen.
If you are trying to quit vaping while on estrogen, it may be worth knowing that the difficulty is not purely willpower. The hormonal environment is working against you in a measurable way. One small study in postmenopausal women found that nicotine replacement therapy (patches) worked just as well in women using hormone replacement as in those not using it, suggesting that nicotine replacement is still a viable quit strategy even when estrogen is on board.
What to Discuss With Your Prescriber
If you are currently vaping and taking any form of estrogen, here are the practical considerations that emerge from this body of evidence:
- Route matters: Transdermal estrogen (patches, gels) avoids the liver-driven clotting surge that oral estrogen causes. If you have any vascular risk factors, including vaping, this distinction could meaningfully change your risk profile.
- Type of estrogen matters: Pills containing estradiol or estetrol carry lower clotting risk than those with ethinyl estradiol. Many newer contraceptive formulations have moved in this direction.
- Nicotine-free is better but not safe: Removing nicotine from your vape liquid reduces platelet activation and some vascular harm, but the heated aerosol itself still causes endothelial damage and oxidative stress.
- Inherited clotting disorders amplify the danger: If you have a family history of blood clots or a known condition like Factor V Leiden, the combined risk from estrogen and vaping is compounded further. Screening may be worth discussing.
- Stroke risk is the particular concern: Smoking (and likely vaping) on estrogen raises arterial clot risk disproportionately, meaning stroke is the event most specifically linked to this combination rather than venous clots alone.
Most prescribers ask whether you smoke before starting estrogen-containing contraception or hormone therapy. Fewer ask specifically about vaping, partly because the direct evidence base is so sparse. But the biological mechanisms that justified the smoking warning apply to vaping with enough consistency that you should volunteer the information. Your prescriber may suggest a progestin-only method (which does not carry the same clot risk), a transdermal estrogen route, or a newer pill formulation, depending on your situation.
How Estrogen Users Get Overlooked in Vaping Research
Much of the foundational research on e-cigarette health effects has been conducted in mixed-sex populations without controlling for hormonal contraception or hormone therapy use. Studies measuring vascular outcomes in young adults, for example, rarely report whether female participants were on birth control, despite the fact that this could profoundly affect the results. The researchers who found worse endothelial function in female vapers compared to male vapers had to conduct a separate sub-analysis to determine whether estradiol levels explained the sex difference. They found they did not, but this kind of hormone-aware analysis remains the exception rather than the rule.
The result is a landscape where millions of people use both e-cigarettes and estrogen simultaneously, but the specific cardiovascular risk of that combination has never been quantified in a large cohort study. Prescribing guidelines still rely on the smoking analogy, which is reasonable but imprecise. E-cigarettes expose users to fewer toxic combustion byproducts than traditional cigarettes, so the magnitude of vascular harm may differ. Whether that means the combined risk with estrogen is somewhat lower, substantially lower, or comparable remains unknown. The gap in the evidence is itself worth knowing about, because it means anyone telling you vaping on estrogen is “definitely fine” or “just as bad as smoking” is guessing. The honest answer is that the risk is real, the mechanisms are documented, and the precise numbers are missing.